Evidence map›Paper›PMID 34734295›Full record

ReviewDer Nervenarzt2022

[Diagnostics and treatment of giant cell arteritis].

Markus Kraemer, Jana Becker, Thorsten Alexander Bley, Andreas Steinbrecher, Jens Minnerup, Bernhard Hellmich

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Der Nervenarzt, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 78% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Markus KraemerKlinik für Neurologie, Alfried Krupp Krankenhaus Rüttenscheid, Alfried-Krupp-Straße 21, 45130, Essen, Deutschland. Markus.kraemer@krupp-krankenhaus.de.
Jana BeckerKlinik für Neurologie, Alfried Krupp Krankenhaus Rüttenscheid, Alfried-Krupp-Straße 21, 45130, Essen, Deutschland.
Thorsten Alexander BleyInstitut für Diagnostische und Interventionelle Radiologie, Universitätsklinikum Würzburg, Würzburg, Deutschland.
Andreas SteinbrecherKlinik für Neurologie, Helios Klinikum Erfurt, Erfurt, Deutschland.
Jens MinnerupKlinik für Neurologie mit Institut für Translationale Neurologie, Universitätsklinikum Münster, Münster, Deutschland.
Bernhard HellmichKlinik für Innere Medizin, Rheumatologie und Immunologie, Medius-Klinik Kirchheim unter Teck, Kirchheim unter Teck, Deutschland.
Alfried Krupp Hospital · DEHelios Klinikum Erfurt · DEKlinik und Poliklinik für Neurologie · DEUniversitätsklinikum Würzburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Giant cell arteritis (GCA) is the most common idiopathic systemic vasculitis in the age group over 50 years. It requires prompt diagnostics and treatment to avoid severe complications, such as visual loss or stroke. The tendency to relapse makes a glucocorticoid (GC) treatment necessary for several years and sometimes lifelong, which increases the risk of GC-induced long-term side effects. Therefore, additive GC-sparing treatment is recommended in the majority of patients. For this purpose, the anti-IL‑6 receptor antibody tocilizumab is available as an approved substance for subcutaneous application; alternatively, methotrexate (MTX) can be used (off-label).

Indexed as

Giant Cell ArteritisDrug Therapy, CombinationGlucocorticoidsHumansMethotrexateMiddle AgedRecurrenceGlucocorticoidsMethotrexateDiagnosisGiant cell arteritisGlucocorticoidsGlucocorticoid-sparing agentsMethotrexateTherapyTocilizumab

Identifiers

PMID34734295
PMCPMC9363349
OpenAlexW3208747516

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.